ArticleArchivos de cardiologia de Mexico2025
[Ductal stenting versus Blalock-Taussig-Thomas fistula in a Latin-American country].
Article in Archivos de cardiologia de Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Patients with congenital heart disease with ductus arteriosus-dependent pulmonary flow have as a palliative procedure the placement of a Blalock-Taussig-Thomas fistula (BTTF) or ductal stent (DSt) and subsequently undergoing to definitive palliation or repair. BTTF has been associated with increased morbidity and mortality. The objective of this research is to compare the morbidity and mortality of BTTF versus DSt, as well as their short- and medium-term outcomes. Methods: The study population was patients undergoing BTTF or DSt placement from January 2012 to December 2022. Results: 164 patients were identified, 128 with BTTF and 36 with DSt. 87.5% of the BTTF group presented complications, and 22.2% of the DSt group (p < 0.001). The OR for BTTF for development of complications was 19.58 (95%CI: 7.79-51.17). Intensive care unit stay was shortzer in DSt compared to FBTT (MD: -4.69 days; 95%CI: -7.30 to -2.07; I2 = 80%; p = 0.0004). The relative risk of FBTT patients for death was 2.32 (95%CI: 0.755-7.149), but there was no statistically significant difference for mortality (p = 0.135). Conclusions: Mortality presented a lower tendency in patients with DSt. However, in other variables such as morbidity, hospital stay and reintervention were less frequent in the DSt group and were statistically significant. This evidence is the first in Latin-America and supports DSt as the safest and most effective option compared to FBTT in our setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.